Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.39% |
| 2 | Financials | 6.67% |
| 3 | Healthcare | 6.18% |
| 4 | Industrials | 4.97% |
| 5 | Consumer Discretionary | 4.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HR
1726
DELISTED
Healthcare Realty Trust Incorporated
HR
| $12.9M | 0.01% |
433,770
-486,614
| -53% | -$14.9M |
|
|
WBA
1727
DELISTED
Walgreens Boots Alliance
WBA
| $12.9M | 0.01% |
274,149
-936,504
| -77% | -$45.2M |
|
|
HCNEU
1728
DELISTED
Jaws Hurricane Acquisition Corp. Unit
HCNEU
| $12.9M | 0.01% |
1,289,791
+8,713
| +0.7% | +$87.2K |
|
1729
Talos Energy
TALO
$2.44B
| $12.9M | 0.01% |
+936,011
| New | +$11.4M |
|
|
CVII
1730
DELISTED
Churchill Capital Corp VII Class A Common Stock
CVII
| $12.9M | 0.01% |
1,325,865
-1,463,204
| -52% | -$14.2M |
|
1731
UiPath
PATH
$6.41B
| $12.9M | 0.01% |
244,716
-8,336
| -3% | -$505K |
|
|
TRCA
1732
DELISTED
Twin Ridge Capital Acquisition Corp.
TRCA
| $12.9M | 0.01% |
1,326,870
+374,293
| +39% | +$3.63M |
|
1733
PUT
MetLife
MET
$62.5B
| $12.9M | 0.01% |
208,300
-315,600
| -60% | -$19M |
|
1734
Sally Beauty Holdings
SBH
$1.46B
| $12.9M | 0.01% |
763,107
+573,719
| +303% | +$10.9M |
|
1735
C4 Therapeutics
CCCC
$405M
| $12.8M | 0.01% |
287,573
-96,975
| -25% | -$4.15M |
|
|
AHPAU
1736
DELISTED
Avista Public Acquisition Corp. II Unit
AHPAU
| $12.8M | 0.01% |
+1,269,543
| New | +$12.8M |
|
|
EWCZ
1737
DELISTED
European Wax Center
EWCZ
| $12.8M | 0.01% |
+458,246
| New | +$11.5M |
|
1738
OSI Systems
OSIS
$3.62B
| $12.8M | 0.01% |
135,386
+48,730
| +56% | +$4.75M |
|
1739
CALL
Neurocrine Biosciences
NBIX
$18.7B
| $12.8M | 0.01% |
133,700
-16,300
| -11% | -$1.54M |
|
|
COR
1740
DELISTED
Coresite Realty Corporation
COR
| $12.8M | 0.01% |
+92,432
| New | +$13.2M |
|
1741
PUT
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$158M
| $12.8M | 0.01% |
28,750
-11,836
| -29% | -$5.31M |
|
|
PACX
1742
DELISTED
Pioneer Merger Corp. Class A Ordinary Share
PACX
| $12.8M | 0.01% |
1,288,985
+201,697
| +19% | +$2M |
|
1743
PUT
NIO
NIO
$12.1B
| $12.8M | 0.01% |
358,800
+280,000
| +355% | +$11.5M |
|
1744
Aemetis
AMTX
$110M
| $12.8M | 0.01% |
698,839
+278,356
| +66% | +$3.08M |
|
|
HERAU
1745
DELISTED
FTAC Hera Acquisition Corp. Units
HERAU
| $12.8M | 0.01% |
1,281,004
-596,848
| -32% | -$5.97M |
|
1746
PUT
Qorvo
QRVO
$8.01B
| $12.7M | 0.01% |
76,100
+70,900
| +1,363% | +$13.2M |
|
|
CHAA
1747
DELISTED
Catcha Investment Corp
CHAA
| $12.7M | 0.01% |
1,299,587
+687,550
| +112% | +$6.66M |
|
1748
Leidos
LDOS
$14.1B
| $12.7M | 0.01% |
131,796
-47,056
| -26% | -$4.67M |
|
1749
CALL
Labcorp
LH
$25.9B
| $12.7M | 0.01% |
52,380
+29,100
| +125% | +$7.33M |
|
1750
NCR Voyix
VYX
$1.12B
| $12.7M | 0.01% |
532,365
+248,104
| +87% | +$6.46M |
|
Similar funds
Millennium Management's Q3 2021 Portfolio in Review
As of Q3 2021, Millennium Management held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Millennium Management deployed $8.65B of net new capital in Q3 2021, opening 1,244 new positions and adding to 2,720 existing holdings. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M.
By sector, the portfolio is most concentrated in Technology at 7.4% of assets, down from 7.8% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $694M trimmed.
- Millennium Management's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Millennium Management added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Millennium Management's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Millennium Management fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Millennium Management's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Millennium Management opened 1,244 new positions and closed 981 in Q3 2021.
- Millennium Management's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.